All In Biotech

Drug Trial Radar · NCT02141139

Perioperative Inflammation and Breast Cancer Outcome

Suppression of Inflammation by Using NSAIDs During Peri-operative Period Can Affect the Prognosis of Breast Cancer.

Last checked: Nov 19, 2026Latest source record: May 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,568 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,568

Planned (sponsor's estimate)

Start

Sep 2014

Primary completion

Jan 2016

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.

Conditions

  • Breast Neoplasms

Interventions

  • NSAIDS (ketorolac and ibuprofen)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. disease free survivalTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.